Compuesto Regulado por la FDA
Este compuesto es aprobado o regulado por la FDA. Comprar sin una receta válida puede violar la ley federal. Verifica todos los requisitos legales en tu jurisdicción.
Tirzepatide
Mounjaro / Zepbound
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly, approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It represents a significant advancement over single-agonist GLP-1 drugs like semaglutide, demonstrating superior weight loss and glycemic control in head-to-head trials. The molecule is a 39-amino acid synthetic peptide with a C20 fatty diacid moiety enabling once-weekly dosing through albumin binding.
Mecanismo de Acción
Dual GIP/GLP-1 receptor agonist. Activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors simultaneously. Produces greater weight loss and glycemic control than single-receptor agonists.
Protocolos de Investigación
Para propósitos de investigación solo. No es asesoramiento médico.
Research protocols start at 2.5mg weekly for 4 weeks, escalating through 5mg, 7.5mg, 10mg, 12.5mg, to a maximum of 15mg weekly.
Notas de Investigación
Clinical Research Status
Tirzepatide received FDA approval for type 2 diabetes (Mounjaro) in May 2022 and for chronic weight management (Zepbound) in November 2023. The SURMOUNT clinical program demonstrated unprecedented weight loss of up to 22.5% at the highest dose in non-diabetic obese adults. Ongoing trials are investigating applications in heart failure with preserved ejection fraction (HFpEF), obstructive sleep apnea, and MASH/NASH.
Key Published Findings
The SURPASS-2 trial showed tirzepatide 15mg was superior to semaglutide 1mg for both HbA1c reduction (-2.46% vs -1.86%) and weight loss (-12.4kg vs -6.2kg). SURMOUNT-1 demonstrated that 22.5% of participants on the 15mg dose achieved greater than 25% body weight loss at 72 weeks. The SURMOUNT-4 trial confirmed that weight regain occurs upon discontinuation, with participants regaining approximately 14% of lost weight after stopping treatment.
Safety Profile
The most common adverse events are gastrointestinal: nausea (12-33%), diarrhea (12-21%), and vomiting (5-12%), generally mild-to-moderate and decreasing with continued use. A boxed warning exists for thyroid C-cell tumors based on rodent studies, though human relevance is uncertain. Pancreatitis, gallbladder events, and hypoglycemia (when combined with sulfonylureas or insulin) are less common but clinically significant risks.
Drug Interactions & Contraindications
Tirzepatide slows gastric emptying, potentially affecting absorption of oral medications, particularly oral contraceptives (backup contraception recommended for 4 weeks after initiation or dose increase). Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Dose adjustments may be needed for insulin and sulfonylureas to prevent hypoglycemia when used in combination.
Comparison to Related Compounds
Head-to-head data from SURPASS-2 shows tirzepatide's superiority over semaglutide for both weight loss and glycemic control, likely attributable to the additive GIP receptor agonism. Unlike semaglutide which is purely a GLP-1 agonist, tirzepatide's dual mechanism may better preserve lean mass during weight loss based on preliminary body composition data. Retatrutide (Eli Lilly's triple agonist adding glucagon receptor activity) represents the next evolution, showing up to 24.2% weight loss in Phase 2 trials.
Community Observations
Available in escalating doses from 2.5mg to 15mg, with recommended titration over 20+ weeks to minimize GI side effects. Supply constraints have been a persistent issue since launch, with many patients experiencing difficulty obtaining prescriptions. Cost without insurance is approximately $1,000-1,100/month, though manufacturer savings programs and compounding pharmacies have expanded access.
Media Vida
~5 days
Reconstitución
Bacteriostatic water (BAC)
Almacenamiento
Liofilizado
Room temperature up to 24 months. Protect from light.
Reconstituído
Refrigerate 2-8C. Use within 21 days.
Estado Legal EE.UU.
También Se Conoce Como
Última Investigación
Highlighting the potential of tirzepatide as a novel dual GIP and GLP-1 receptor agonist for managing type 2 diabetes, focusing on its efficacy and safety profile.
Highlighting the efficacy and safety profile of modern anti-obesity drugs, focusing on liraglutide, semaglutide, and tirzepatide.
Highlighting the latest advancements and considerations for clinicians using GLP-1 receptor agonists and tirzepatide in treating type 2 diabetes and obesity.
Preguntas frecuentes
¿Qué es Tirzepatide?
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly, approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It represents a significant advancement over single-agonist GLP-1 drugs like semaglutide, demonstrating superior weight loss and glycemic control in head-to-head trials. The molecule is a 39-amino acid synthetic peptide with a C20 fatty diacid moiety enabling once-weekly dosing through albumin binding.
¿Cómo funciona Tirzepatide?
Dual GIP/GLP-1 receptor agonist. Activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors simultaneously. Produces greater weight loss and glycemic control than single-receptor agonists.
¿Cuál es el estado regulatorio de Tirzepatide en EE. UU.?
FDA-approved (Rx only)
¿Cuál es la vida media de Tirzepatide?
~5 days
¿Qué otros nombres tiene Tirzepatide?
Mounjaro, Zepbound
Peptide Contacts proporciona resúmenes basados en investigaciones únicamente para fines informativos. No hospedamos, distribuimos ni endosamos la documentación del proveedor. Todos los certificados de análisis, certificados GMP y comunicaciones del proveedor deben solicitarse y verificar directamente por el comprador. Nada en esta plataforma constituye asesoramiento legal, médico o profesional. Los usuarios son únicamente responsables de verificar las credenciales del proveedor y asegurarse de cumplir con todas las leyes locales, estatales y federales aplicables antes de comprar cualquier químico de investigación. El uso de esta plataforma constituye aceptación de toda la responsabilidad personal.
Leer aviso completo